Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Myval TAVR valve associated with positive durability data after 4 years
Researchers have been spending more and more time evaluating the Myval TAVR valve from Indian medtech company Meril Life Sciences. The balloon-expandable device is available in some parts of the world, but not the United States.
Medicare now covers TriClip procedures for patients with symptomatic tricuspid regurgitation
CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development.
New TAVR valve from MiRus linked to positive early outcomes
The Siegel TAVR valve includes no nickel or cobalt. In fact, its frame was built using special alloys specifically developed by MiRus.
Cusp overlap technique improves TAVR outcomes, new meta-analysis confirms
The new study, based on 14 different clinical trials, highlights why so many care teams have already adopted the cusp overlap technique when implanting self-expanding TAVR valves.
At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.

A team of researchers at Gladstone, including Bárbara González Terán shown here seated, developed a novel algorithm method for identifying genetic variants that are likely to play important roles in congenital heart disease. This opens up opportunities to accelerate research into this serious condition. Photo by Michael Short/Gladstone Institutes

Algorithm helps sort genetic data to improve our understanding of congenital heart disease

Researchers at Gladstone Institutes developed a new algorithm method for identifying genetic variant combinations that are likely to play important roles in congenital heart disease.

Amyloidosis patients can safely undergo TAVR

Researchers focused on 30-day outcomes, sharing their findings in the American Journal of Cardiology.

New risk score predicts mortality after TEER

Researchers developed the new algorithm by identifying eight key factors associated with mortality among TEER patients.

TAVR-related stroke, the authors wrote, is a "critically important and potentially preventable source of patient morbidity."

Tricuspid valve annuloplasty during mitral valve surgery offers key benefits

The new analysis focused on 98 patients who presented with primary mitral regurgitation.

Seeking Out Severe Aortic Stenosis: The Low Down on Low Flow-Low Gradient

Structural Heart Disease

Myval TAVR valve associated with positive durability data after 4 years

Medicare now covers TriClip procedures for patients with symptomatic tricuspid regurgitation

New TAVR valve from MiRus linked to positive early outcomes

Cusp overlap technique improves TAVR outcomes, new meta-analysis confirms

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving